The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to
placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
Primary objectives:
- To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR).
Secondary objectives:
- To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other
lipoprotein kinetics.
- To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters
- To assess effect of Rimonabant on body composition
- To assess safety of Rimonabant